Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 8/20 | 0.35 |
| ▸ | HTR2B | P41595 | 6/20 | 0.35 |
| ▸ | HTR2A | P28223 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104919 | 1.00 | CCR5 (0.43) | CCR5TOP2AHTR2CHTR2BHTR2A | |
| SCHEMBL7496126 | 1.00 | CCR5 (0.43) | CCR5TOP2AHTR2CHTR2BHTR2A | |
| SCHEMBL4102126 | 1.00 | CCR5 (0.43) | CCR5TOP2AHTR2CHTR2BHTR2A | |
| SCHEMBL4110226 | 0.86 | CYP3A4 (0.40) | HTR2CHTR2BHTR2AKDM1A | |
| SCHEMBL4100379 | 0.86 | CYP2A6 (0.38) | CCR5KDM1AMAPT | |
| SCHEMBL6104505 | 0.85 | HTR2C (0.42) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL7499691 | 0.85 | HTR2C (0.42) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL4104772 | 0.83 | HTR2C (0.46) | HTR2CHTR2BHTR2AKDM1AMAPT | |
| SCHEMBL7498178 | 0.82 | THRB (0.30) | — | |
| SCHEMBL7496731 | 0.82 | THRB (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | CCR5 1050/4885TOP2A 4700/4885HTR2C 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.